Clarithromycin
/ Clarithromycin /, Clarithromycin, Omeclamox-pak, Voquezna Triple (clarithromycin) is a small molecule pharmaceutical. Clarithromycin was first approved as Biaxin on 1991-10-31. It is used to treat bacterial infections, bronchitis, chlamydia infections, duodenal ulcer, and haemophilus infections amongst others in the USA. The pharmaceutical is active against androgen receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Clarithromycin (discontinued: Biaxin, Clarithromycin)
CombinationsLansoprazole, amoxicillin clarithromycin, Voquezna triple (discontinued: Lansoprazole, amoxicillin clarithromycin, Omeclamox-pak, Prevpac)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Clarithromycin
Amoxicillin
+
Clarithromycin
+
Lansoprazole
Amoxicillin
+
Clarithromycin
+
Omeprazole
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| OMECLAMOX-PAK | Cumberland Pharmaceuticals | N-050824 DISCN | 2011-02-08 | 1 products, RLD |
Hide discontinued
Amoxicillin
+
Clarithromycin
+
Vonoprazan fumarate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VOQUEZNA TRIPLE PAK | Phathom Pharmaceuticals | N-215152 RX | 2022-05-03 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| biaxin | New Drug Application | 2012-02-22 |
| clarithromycin | ANDA | 2025-02-05 |
| clarithromycin clarithromycin | ANDA | 2018-02-14 |
| clarithromycin extended release | 2008-08-08 | |
| lansoprazole, amoxicillin, clarithromycin | ANDA | 2024-01-23 |
| omeclamox-pak | New Drug Application | 2023-08-17 |
| prevpac | New Drug Application | 2010-03-15 |
| voquezna dual pak voquezna triple pak | New Drug Application | 2024-08-05 |
Indications
FDA
EMA
Show 17 more
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
AMOXICILLIN / CLARITHROMYCIN / VONOPRAZAN FUMARATE, VOQUEZNA TRIPLE PAK, PHATHOM | |||
| 2032-05-03 | GAIN | ||
| 2027-05-03 | NCE | ||
ATC Codes
A: Alimentary tract and metabolism drugs
— A02: Drugs for acid related disorders
— A02B: Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
— A02BD: Combinations for eradication of helicobacter pylori
— A02BD04: Pantoprazole, amoxicillin and clarithromycin
— A02BD05: Omeprazole, amoxicillin and clarithromycin
— A02BD06: Esomeprazole, amoxicillin and clarithromycin
— A02BD07: Lansoprazole, amoxicillin and clarithromycin
— A02BD09: Lansoprazole, clarithromycin and tinidazole
— A02BD11: Pantoprazole, amoxicillin, clarithromycin and metronidazole
— A02BD12: Rabeprazole, amoxicillin and clarithromycin
— A02BD14: Vonoprazan, amoxicillin and clarithromycin
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01F: Macrolides, lincosamides and streptogramins
— J01FA: Macrolides
— J01FA09: Clarithromycin
HCPCS
No data
Clinical
Clinical Trials
523 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | 9 | 20 | 39 | 88 | 73 | 219 |
| Helicobacter infections | D016481 | EFO_1000961 | — | 1 | 10 | 20 | 44 | 38 | 106 |
| Communicable diseases | D003141 | — | — | 3 | 9 | 16 | 29 | 29 | 82 |
| Gastritis | D005756 | EFO_0000217 | K29.7 | 2 | 3 | 11 | 26 | 8 | 48 |
| Healthy volunteers/patients | — | — | — | 34 | — | — | 1 | 6 | 41 |
| Mycobacterium infections | D009164 | — | A31.9 | 1 | 10 | 10 | 2 | 4 | 24 |
| Pneumonia | D011014 | EFO_0003106 | J18 | 1 | 1 | 13 | 5 | 3 | 22 |
| Mycobacterium avium-intracellulare infection | D015270 | EFO_0007386 | — | 1 | 7 | 7 | 3 | 3 | 20 |
| Dyspepsia | D004415 | EFO_0008533 | K30 | 2 | 1 | 1 | 12 | 4 | 20 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 4 | 5 | 4 | 1 | 3 | 17 |
Show 67 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 2 | 18 | 4 | — | — | 22 |
| Plasma cell neoplasms | D054219 | — | — | 2 | 18 | 4 | — | — | 22 |
| Lymphoma | D008223 | — | C85.9 | 2 | 5 | 1 | — | 4 | 12 |
| Covid-19 | D000086382 | — | U07.1 | 1 | 2 | 4 | — | 1 | 7 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 2 | 1 | 1 | — | 2 | 5 |
| Aggressive periodontitis | D010520 | EFO_0006342 | K05.2 | — | 2 | 2 | — | 2 | 4 |
| Aggression | D000374 | EFO_0003015 | — | — | 2 | 2 | — | 2 | 4 |
| Acute disease | D000208 | — | — | — | — | 1 | — | 3 | 4 |
| Buruli ulcer | D054312 | EFO_1001281 | A31.1 | — | 3 | 2 | — | — | 3 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | — | 1 | — | 2 | 3 |
Show 41 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | — | 3 | — | — | 4 | 7 |
| Neoplasms | D009369 | — | C80 | 3 | 1 | — | — | — | 4 |
| B-cell lymphoma | D016393 | — | — | 1 | 1 | — | — | 1 | 3 |
| Disorders of excessive somnolence | D006970 | — | G47.1 | — | 2 | — | — | 1 | 3 |
| Lung neoplasms | D008175 | — | C34.90 | — | 2 | — | — | — | 2 |
| Narcolepsy | D009290 | EFO_0000614 | G47.4 | — | 2 | — | — | — | 2 |
| Idiopathic hypersomnia | D020177 | — | G47.11 | — | 2 | — | — | — | 2 |
| Leukemia | D007938 | — | C95 | 1 | 1 | — | — | — | 2 |
| Lymphoid leukemia | D007945 | — | C91 | 1 | 1 | — | — | — | 2 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | 1 | — | — | — | 1 |
Show 20 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug interactions | D004347 | — | — | 8 | — | — | — | 1 | 9 |
| Pharmacokinetics | D010599 | — | — | 5 | — | — | — | — | 5 |
| Long qt syndrome | D008133 | HP_0001657 | I45.81 | 1 | — | — | — | 1 | 2 |
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | 1 | — | — | — | — | 1 |
| Thromboembolism | D013923 | — | — | 1 | — | — | — | — | 1 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | — | 1 |
| Oxidative stress | D018384 | EFO_1001905 | — | 1 | — | — | — | — | 1 |
| Mycoses | D009181 | — | B35-B49 | 1 | — | — | — | — | 1 |
Show 7 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tracheitis | D014136 | EFO_0007518 | — | — | — | — | — | 3 | 3 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | — | — | 2 | 2 |
| Patient compliance | D010349 | — | — | — | — | — | — | 2 | 2 |
| Gastrointestinal microbiome | D000069196 | — | — | — | — | — | — | 2 | 2 |
| Delirium | D003693 | — | R41.0 | — | — | — | — | 1 | 1 |
| Torsades de pointes | D016171 | EFO_0005307 | I47.21 | — | — | — | — | 1 | 1 |
| Staphylococcal infections | D013203 | — | A49.01 | — | — | — | — | 1 | 1 |
| Staphylococcus aureus | D013211 | NCBITaxon_1280 | — | — | — | — | — | 1 | 1 |
| Critical illness | D016638 | — | — | — | — | — | — | 1 | 1 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 1 | 1 |
Show 22 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Clarithromycin |
| INN | clarithromycin |
| Description | Clarithromycin is the 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis. It has a role as an antibacterial drug, a protein synthesis inhibitor, an environmental contaminant and a xenobiotic. |
| Classification | Small molecule |
| Drug class | antibiotics (Streptomyces strain) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O |
Identifiers
| PDB | — |
| CAS-ID | 81103-11-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1741 |
| ChEBI ID | 3732 |
| PubChem CID | 84029 |
| DrugBank | DB01211 |
| UNII ID | H1250JIK0A (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Clarithromycin
+
Amoxicillin
+
Lansoprazole
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Clarithromycin
+
Amoxicillin
+
Omeprazole
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Clarithromycin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 27,554 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
31,159 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use